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Abstract
Background: Patients with primary immunodeficiency (PID) often suffer from frequent respiratory tract infections. Despite
standard treatment with IgG-substitution and antibiotics many patients do not improve significantly. Therefore, we
hypothesized that additional immune deficits may be present among these patients.
Objective: To investigate if PID patients exhibit impaired production of antimicrobial peptides (AMPs) in nasal fluid and a
possible link between AMP-expression and Th17-cells.
Methods: Nasal fluid, nasopharyngeal swabs and peripheral blood mononuclear cells (PBMCs) were collected from patients
and healthy controls. AMP levels were measured in nasal fluid by Western blotting. Nasal swabs were cultured for bacteria.
PBMCs were stimulated with antigen and the supernatants were assessed for IL-17A release by ELISA.
Results: In healthy controls and most patients, AMP levels in nasal fluid were increased in response to pathogenic bacteria.
However, this increase was absent in patients with common variable immunodeficiency (CVID) and Hyper-IgE syndrome
(HIES), despite the presence of pathogenic bacteria. Furthermore, stimulation of PBMCs revealed that both HIES and CVID
patients exhibited an impaired production of IL-17A.
Conclusion: CVID and HIES patients appear to have a dysregulated AMP response to pathogenic bacteria in the upper
respiratory tract, which could be linked to an aberrant Th17 cell response.
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Introduction
Diseases that are characterized by lack of antibodies (hypogam-
maglobulinemias, HGGs) include syndromes such as selective IgA-
deficiency, IgG-deficiency and common variable immunodeficien-
cy (CVID). Common symptoms include frequent bacterial res-
piratory tract infections (RTIs), fatigue as well as autoimmune
manifestations [1]. Bacteria are the most common infectious agent,
although viral, fungal and protozoal infections may also occur [2–
5]. Standard treatment involves antibiotic therapy and patients
with low levels of IgG and/or IgA are administered IgG prepara-
tions, which in most cases reduce symptoms and improve overall
health [6]. Nevertheless, many patients still experience frequent
infections. Hence, it is possible that immune deficits other than
lack of immunoglobulins may be involved in some of these
disorders. Such immune deficits could include two key compo-
nents of the innate and adaptive immune system, namely
antimicrobial peptides (AMPs) and Th17 cells.
AMPs are expressed by immune and epithelial cells and
constitute an essential part of innate immunity [7]. They are
released early during infection and have potent antimicrobial
activities against a wide range of microbes. AMPs also induce
chemotaxis of neutrophils and macrophages, which are rapidly
recruited to the site of infection [8]. AMPs have been implicated in
several human diseases, including psoriasis [9,10], Crohn’s disease
[11], cystic fibrosis [12] and tuberculosis [13].
Th17 cells constitute a recently discovered subset of T helper cells
characterized by expression of the transcription factor RORcta n d
secretion of IL-17 and IL-22 [14]. They are instrumental in mucosal
immunity by orchestrating AMP expression in epithelial cells as well as
by recruiting neutrophils to mucosal tissues [15]. Th17 cells are
generally considered to be pro-inflammatory and have been shown to
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more, studies using animal models have demonstrated a role for Th17
cells in mediating protection against several different bacteria and
fungi, suggesting dual and context-dependent roles for Th17 cells
[17,18]. Recently, a number of human disorders characterized by
infectious susceptibility and low numbers of Th17 cells have been
described, including Hyper-IgE syndrome (HIES) [19] and chronic
mucocutaneous candidiasis [20]. Special focus has been given to HIES,
a PID characterized by frequent skin and RTIs together with distinct
skeletal abnormalities and very high levels of serum-IgE. The HIES
diagnosis is obtained by genetic analysis of the STAT3 gene [21].
Here we sought to investigate whether induction of AMPs and
Th17 cell responses are impaired in PID patients with frequent
RTIs. We collected nasopharyngeal (NPH) swabs, nasal fluid and
peripheral blood mononuclear cells (PBMC) from patients with
selective IgA-, or IgG-deficiencies, CVID, or with frequent RTIs
without a defined diagnosis (Not Defined, ND group). In addition,
two patients with HIES carrying mutations in the STAT3 gene
were enrolled. NPH swabs were screened for bacterial growth
while nasal fluid samples were investigated for AMP expression,
IL-8 levels and induction of neutrophil chemotaxis. PBMCs were
challenged with antigens and IL-17A was measured in the
supernatant. Finally, a clinical scoring system was used to assess
the clinical status of the patient at the time of inclusion.
Methods
Ethics statement
The study was approved by the Regional Ethical Committee in
Stockholm, FE 289, Nobels va ¨g 9, Karolinska Institutet, 171 77
Stockholm, Sweden (DNR 2007/751-31/1-4) and written in-
formed consent was collected from all patients prior to inclusion
and sample-collection.
Patients and healthy controls
All patients were recruited at the Immune Deficiency Unit,
Karolinska University Hospital, Huddinge. The diagnostic criteria
were the following: XLA (D80.0): a mutation in the btk-gene
leading to a total lack of endogenous synthesis of immunoglobulins
(n=3). CVID (D83.0): serum-IgG,3 g/l, serum-IgA,0.07 g/l
and a lack of IgG response to pneumo-coccal polysaccharide
vaccination (Pneumovax). No other diagnosis should explain the
lack of IgG and IgA (n=18). IgG-subclass deficiency (D80.3):
serum-IgG1,2.8 g/l; s-IgG2,1.15 g/l; s-IgG3,0.24 g/l (n=55
for the whole group of subclass deficiencies) or total serum
IgG,6.7 g/l (n=9). Selective IgA-deficiency (D80.2): serum-
IgA,0.07 g/l and normal IgM- and IgG-levels (n=16). All IgA-
deficient patients included in the study exhibited at least four
bacterial sinopulmonary infections per year. To obtain sufficient
numbers for statistical calculations XLA, IgG-deficiency and
selective IgA-deficiency were analyzed together in the results-
section. HIES (D82.4): mutation analysis of the STAT3 gene was
performed bythe Grimbacherlab (UCL Schoolof Life andMedical
Sciences, London), (n=2). Patient HIES1 had a heterozygous
mutation (Y657C) and serum IgE of 7600 units. Patient HIES2 had
a heterozygous mutation (R382L) and serum IgE of 23000 units.
Patients with increased numbers of respiratory tract
infections (Not Defined, ND-group, D89.9): at least 4 RTIs
per year during the last 2 years that required antibiotic treatment
and/or recurrent episodes of virus-like symptoms with muscle pain,
malaise and fever during at least 3 months per year during the last 2
years, with significant negative impact on quality of life (n=30). 26
healthy controls were recruited as well as 5 control individuals with
ongoing infections and symptoms from the respiratory tract, such as
runny nose, cough and malaise.
Clinical scoring system
On the day of study inclusion, the patients were investigated by
a physician who recorded the following symptoms: symptoms from
ears, sinuses, nose, bronchitis, pneumonia, cough, runny nose, sore
throat, fever, fatigue or malaise. Each symptom was given 1 point
and the scoring range was between 0 points (no symptoms) and 11
points (maximum score).
Sampling of nasal fluid, NPH swabs
A nasopharyngeal swab was taken from one nostril and sent to
the Clinical Microbiology Laboratory at Karolinska University
Hospital, Huddinge for bacterial culture. The bacterial content was
evaluated as either ‘‘no growth of bacteria’’, ‘‘normal flora’’ (typical
findings include alpha haemolytic streptococci, corynebacteria spp,
commensal Neisseria spp. and other non-pathogenic strains) or
‘‘pathogenic growth’’ (defined here as H. influenzae, S. aureus, S.
pneumoniae,M.catharralis and enterobacteriacae spp).Subsequently,nasal
fluid was collected through a thin plastic tube carefully inserted into
the back of the nose using the other nostril as entry port (10–12 cm
fromthenostrilmeatus).5–10 mlofsalinewasadministeredpriorto
sampling in order to make the epithelial lining moist and to dissolve
mucus depositions. A gentle vacuum was applied and 3–5 ml nasal
fluid was collected and stored at 220uC.
Extraction of peptides and proteins from nasal fluid
Nasal fluid (3–5 ml) was extracted in an equal volume (1:1) of
60% acetonitrile (AcN) in 1% trifluoroacetic acid (TFA) over night
at 4uC. The extract was centrifuged at 3500 g and the supernatant
was lyophilized. The lyophilized extract was resuspended in 0.1%
TFA and enriched for polypeptides using solid phase extraction as
described in [22]. The lyophilized polypeptide extract was re-
constituted in 0.1% TFA to a concentration of 5 mg/mla s
determined spectrophotometrically using a Nanodrop-system
(Thermo Scientific, Wilmington, U.S.).
Lithium dodecyl sulfate polyacrylamide gel
electrophoresis (LDS-PAGE) and Western blotting
The concentrated and lyophilized extract (25 mg) was dissolved
in lithium dodecyl sulphate (LDS) sample buffer, 50 mM
Dithiothreitol (DTT) (Sigma-Aldrich, St. Louis, Missouri, USA)
and incubated at 70uC for 10 min. The samples were then
separated using LDS-PAGE and blotted onto PVDF membranes
as described in [22]. Antibodies used were a LL-37 monoclonal
[23] and a HNP1–3 goat polyclonal (sc-22916, Santa Cruz, Santa
Cruz, Calif., USA). Proteins and peptides were visualized on
chemiluminescence film with ECL plus Western blot detection
system (GE Healthcare, Buckinghamshire, United Kingdom).
Concentrations of LL-37 and HNP1–3 in nasal fluid were
determined by densitometry using the software ImageJ (http://
rsbweb.nih.gov/ij/). The intensity of each band was normalized to
an external standard on each membrane and the total amount of
LL-37 and HNP1–3 was determined by multiplying the
densitometric result (ng peptide/mg extract) with the total amount
of polypeptide-extract (mg). Thus, the values represent the total
amount of LL-37 and HNP1–3 from each nasal fluid sample.
Enzyme-linked immunosorbent assay (ELISA) of IL-8 and
HBD-2
The concentrated extracts were diluted 1:500 and 1:3000 in
sample diluent for the HBD-2 (Alpha diagnostic, Texas, USA) and
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respectively. ELISAs were performed according to the manufac-
turers’ instructions and samples were run in triplicate in two
independent experiments.
Isolation of polymorphonuclear leukocytes (PMNs)
Human PMNs were isolated from freshly prepared buffy coats
from healthy donors (Karolinska Hospital Blood Bank, Stockholm,
Sweden) in accordance with [22]. PMNs were suspended to 10
6
cells/mL in HBSS (Invitrogen, Carlsbad, CA, USA). The viability
of PMNs was determined with Trypan blue (Invitrogen, Carlsbad,
CA, USA) staining.
Neutrophil chemotaxis
PMN chemotaxis was measured in a modified Boyden chamber
assay. Briefly, 10
5 human PMNs in HBSS (Invitrogen, Carlsbad,
CA, USA) were added to the upper chamber of a 3 mm pore
polycarbonate Transwell culture insert plate (Corning, NY, USA)
and incubated at 37uC for 2 hours in the absence or presence of
10 mg concentrated nasal fluid extract in the lower chamber. IL-8
(10 nM) (BD Pharmingen, San Diego, CA, USA) was used as a
positive control for migration across the filter. The filters had
previously been blocked with 0.1% BSA in PBS for 30 min. To
efficiently remove all transmigrated cells from the lower chamber,
a final concentration of 10 mM EDTA was added to each well and
cells were resuspended. Thereafter, the cell number was
determined in a FACSCalibur (Beckton Dickinson, San Jose,
CA, USA) by gating on the forward and side scatter character-
istics.
Stimulation of PBMCs and IL-17A ELISA
PBMCs were isolated from whole blood using Lymphoprep,
according to the manufacturer’s instructions. Cryopreserved
PBMCs were quickly thawed at 37uC, washed twice and
resuspended in IMDM (Sigma-Aldrich), supplemented with 10%
heat-inactivated FCS and 2 mM L-glutamine (Invitrogen).
PBMCs (5610
5 cells per well) were stimulated with 20 mg/ml
Candida albicans antigen (Greer Labs, Lenoir, NC, USA) or
100 ng/ml Staphylococcal enterotoxin B (SEB) (Sigma-Aldrich)
in 96-well flat bottom plates. Experiments were performed in
triplicates and stimulated cells were incubated at 37uCi na
humidified atmosphere with 5% CO2. Supernatants were
collected after 5 days of stimulation and stored at 220uC until
assayed for IL-17A using a Ready-SET-Go! ELISA kit
(eBioscience, San Diego, CA, USA), performed according to the
manufacturer’s instructions.
Statistical methods
Data was processed using the softwares Microsoft Excel and
Graph Pad Prism. Normal distribution tests were performed and
most data sets were found to be non-normally distributed. Thus,
non-parametric tests (Mann Whitney U-test) were used where
applicable. Two-sided tests were used for all analyses and p-
values,0.05 were considered significant.
Results
Clinical characteristics of patients and healthy controls
A total of 155 samples were collected from patients with various
PID diagnoses and healthy controls (Table 1). All patients
submitted a clinical scoring card (see Methods for details) before
sample collection. No significant differences were found in clinical
score between the different groups (p=0.23, Kruskal-Wallis test).
Healthy individuals with an ongoing infection exhibited a clinical
score of 4.4, however, a positive bacterial culture was only
detected in 40% of these patients, indicating that the sampling
method used has a low specificity [24] or that also viral infections
could be involved [2]. A total of 23% (range 0–50%) of all
individuals in the study exhibited growth of a primary pathogen in
nasal swabs, including the healthy controls with a clinical score of
zero. There was no correlation between the clinical score and the
presence of potentially pathogenic bacteria in the NPH culture.
Out of all patients, 51% were treated with IgG-substitution, with
the highest treatment fraction in XLA, HIES- and CVID patients
(Table 1), which is in line with current guidelines [25]. In fact,
XLA- and CVID-patients are subjected to lifelong IgG replace-
ment therapy based on the fact that they have an impaired
endogenous production of immunoglobulins [26]. Also patients
with IgG subclass deficiencies have been shown to benefit from
IgG replacement therapy [27]. Moreover, in our centre we
evaluate the efficacy of IgG substitution to selected patients with
frequent bacterial infections but with normal IgG-levels [28].
Table 1. Clinical characteristics of patients and controls.
Diagnosis No of samples % P growth (n samples) Clin Score (average) % Ig-subst (n samples)
Healthy Controls 26 12 (3) 0.0 0 (0)
Infected Controls 5 40 (2) 4.4 0 (0)
Not Defined Immunodeficiency (ND) D89.9 30 33 (10) 2.5 47 (14)
IgA/IgG group (IgA, IgG, XLA) 74 19 (14) 3.1 64 (47)
-Selective IgA-deficiency D80.2 16 31 (5) 2.6 38 (6)
-IgG subclass deficiency D80.3 55 15 (8) 3.2 69 (38)
-XLA D80.0 3 33 (1) 3.7 100 (3)
HIES D82.4 2 50 (1) 5.5 100 (2)
CVID D83.0 18 28 (5) 2.6 89 (16)
Total 155 23 (35) 3.0 51 (79)
% P growth=Percent of samples with growth of bacterial pathogens in the nasopharynx. The values in brackets designate the number of samples with growtho fa
pathogen.
Clin Score=clinical score from 0 (no symptoms)2to 11 (for details see the Methods section).
% Ig-subst=Percent of patients that receive immunoglobulin treatment.
doi:10.1371/journal.pone.0029316.t001
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levels of AMPs in nasal fluid
AMP levels in nasal fluid were determined by Western blot
analysis and subsequent densitometric measurements. Interesting-
ly, patients and healthy controls colonized with a primary
pathogen, here defined as Moraxella catarrhalis, Staphylococcus aureus,
Haemophilus influenzae, Streptococcus pneumoniae and Enterobacteriaceae
spp., exhibited significantly increased levels of AMPs (LL-37,
Fig. 1A; HNP1–3, Fig. 1B) compared to individuals with a
negative bacterial culture. Furthermore, LL-37 levels in nasal fluid
from individuals with normal flora were not significantly elevated
compared to individuals where no bacteria were detected (Fig. 1A).
However, HNP1–3 levels were significantly increased if normal
flora was detected compared to samples from individuals with no
growth (Fig. 1B). Bacteria associated with the highest AMP
concentrations were H. influenzae, S. aureus and S. pneumoniae (Fig. 1C
and D, respectively). AMP levels associated with growth of
Enterobacteriacae spp. and M. catarrhalis were not significantly
elevated (Fig. 1C and D).
Expression of AMPs in nasal fluid is the result of a
dynamic response to bacteria
AMP levels were measured in nasal fluid samples from 26 healthy
individuals and from 5 previously healthy individuals which were
defined by the clinical score as having on-going infections, (See
Materials & Methods for details and Table 1). For two healthy
infected individuals (Control A, female, age 36 and Control B, male,
age 38), samples were obtained on two consecutive days (Fig. 2A and
B). Nasal swabs were cultured for the presence of bacteria and levels
of LL-37 and HNP1–3 were determined. Control A had a negative
bacterial culture day 1 (no growth, NG) and growth of normal flora
(NF) day 2. This change in bacterial composition had only a
moderate impact on LL-37 and HNP1–3, which is in line with
previous results (Fig. 1A and B). Control B had no growth of bacteria
Figure 1. Bacterial composition and levels of AMPs in nasal fluid. AMP levels in nasal fluid samples were determined by Western blotting and
subsequent densitometric measurements and the results were correlated to bacterial growth in the nasopharynx. The levels of LL-37 (A and C) and
HNP1–3 (B and D) are expressed as nanogram peptide/total nasal fluid extract (mg). The group that exhibited growth of primary pathogens was
further subdivided according to bacterial species (C and D). The number of samples included (no growth, normal flora, and pathogen respectively)
are n=44, 43, and 30 (A), n=39, 34, and 28 (B). The number of samples included (no growth, normal flora, H. influenzae, M. catarrhalis, S. aureus,
Enterobacteriacae, S. pneumoniae respectively) are n=44, 43, 8, 3, 11, 3, 5 (C), n=39, 34, 7, 3, 11, 2, 5 (D). Statistical analyses were performed with
Mann Whitney U-test and the standard error of the mean (SEM) was used to estimate sample variation.
doi:10.1371/journal.pone.0029316.g001
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isolated day 2. In accordance with results presented in Figure 1A and
B, this individual exhibited an increased production of both LL-37
and HNP1–3 in response to colonization with a pathogen. Notably,
control A with a clinical score of 5 exhibited high levels of both LL-37
and HNP1-, despite the absence of pathogenic bacteria in the nasal
swab. Thus, a possible explanation for this finding is that a viral
infection caused control A’s symptoms through a local inflammation
and subsequent AMP-release. In contrast, control B had an initial
score of 3, which decreased to 2 on the second day of sampling,
despite being culture-positive for S. pneumoniae. Therefore the rapid
AMP release in control B is most likely explained by a transient
pneumococcal colonization rather than a symptomatic infection.
Again, these data imply that the regulation of AMPs occurs
independently of clinical symptoms. When the total group of healthy
and infected controls was evaluated, a significant induction of both
LL-37 (n=18, p=0.0396, Fig. 2C) and HNP1–3 (n=12, p=0.0217,
Fig. 2D) in response to primary pathogens was detected, supporting
the results presented in Figure 2A and B. A nasal swab with growth of
‘‘normal flora’’ was not associated with a significant induction of LL-
37 or HNP1–3 (Figure 2C and D) in these healthy controls.
Release of AMPs in response to pathogenic bacteria is
significantly impaired in CVID and HIES patients
Next, the AMP response in the immunodeficient patient groups
with regard to bacterial pathogens in the nasopharynx was studied
(Fig. 3A and B). A significant increase in LL-37 levels was observed
in controls colonized by pathogens (same data as in fig. 2C). This
increase in AMP-levels was also true for patients with no
determined immune disorder (N.D. group) and for the IgA/IgG
group (Fig. 3A). XLA-patients (n=3) had an AMP-response to
pathogenic bacteria in the same range as healthy controls (data not
shown) and were presented together with the IgA/IgG-group in
figure 3A and B. HNP1–3 levels in the control group and in IgA/
IgG patients were also significantly increased when pathogens
were present, and while a similar trend was noted for the N.D.
group, it did not reach statistical significance (Fig. 3B). Notably,
there was no increase in neither LL-37 nor HNP1–3 in the CVID
or HIES patients, despite bacterial growth (Fig. 3A and B, table 2).
In fact, both HIES patients completely lacked HNP1–3 in the
nasal fluid (Fig. 3B).
Chemotactic activity of nasal fluid towards healthy
control neutrophils
We then wanted to investigate the reason for the dysregulated
release of AMPs into nasal fluid of HIES and CVID patients.
Nasal fluid derived from patients and controls was investigated for
neutrophil chemotaxis using neutrophils isolated from healthy
control individuals (Fig. 3C). These results revealed that nasal fluid
collected from the N.D group exhibited a chemotactic activity that
was indistinguishable from control individuals (Fig. 3C). In
contrast, patients with IgA/IgG-deficiency and CVID showed
Figure 2. AMP response in nasal fluid of healthy controls. Two previously healthy controls (A, female, age 36; B, male, age 38) were sampled
for nasal fluid on two consecutive days and AMP levels were determined. The total levels of LL-37 (A) and HNP1–3 (B) are expressed as nanogram
peptide/total nasal fluid extract (mg). The clinical score prior to sampling was also measured (A and B). The whole group of controls (both healthy and
infected controls as determined by the clinical score) was analyzed for levels of LL-37 (n=18) (C) and HNP1–3 (n=12) (D). The number of samples (no
growth, normal flora, pathogen, respectively) are n=7, 8, and 3 (C), n=7, 3, and 2 (D). Error bars depict the SEM of the samples (C and D).
doi:10.1371/journal.pone.0029316.g002
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(Fig. 3C). Unexpectedly, the two HIES-patients exhibited the same
chemotactic activity as control individuals (table 2).
To further dissect the chemotactic activity of nasal fluid, the
concentration of the main chemoattractant for neutrophils, IL-8,
was determined by ELISA. There was a weak - although
statistically significant - correlation between the chemotactic
activity and IL-8 levels in nasal fluid, indicating a contribution
of this cytokine to the observed chemotaxis (p=0.0304 and
R
2=0.1469) (Fig. 3D). Notably, HIES patients 1 and 2 appeared
in the upper right quadrant of the figure, indicating high
chemotactic activity as well as high IL-8 levels (Fig. 3D, marked
with ‘‘1’’ and ‘‘2’’, respectively).
PBMCs from CVID and HIES patients release low levels of
IL-17A
To investigate if AMP expression in nasal fluid could be
correlated with the IL-17A response from circulating immune
cells, we measured release of IL-17A in stimulated PBMCs from
patients and healthy controls (Fig. 4). PBMCs were isolated from
whole blood and stimulated for 5 days with Candida antigen
(Fig. 4A) or Staphylococcal Enterotoxin B (SEB) (Fig. 4B). IL-17A
production in PBMCs isolated from healthy controls, IgA/IgG
patients as well as from patients of the N.D. group, exhibited a
similar and robust increase in IL-17A after stimulation. As
expected, samples from HIES patients contained very low levels
Figure 3. AMP response and chemotaxis in relation to diagnosis. AMP levels were studied according to diagnosis and presence of bacterial
pathogens. ‘‘No growth’’ designates negative bacterial cultures and ‘‘Pathogen’’ designates growth of a primary bacterial pathogen (A and B). The
number of samples included (control, ND, IgA/IgG, HIES, and CVID respectively with and without growth) are n=7, 3, 11, 9, 27, 14, 1,1, 6, 4 (A), n=7, 2,
11, 10, 28, 13, 1,1, 6, 4 (B). The chemotactic capacity was determined for samples from each diagnostic group and is expressed as percent migrated
neutrophils (C). The numbers of samples in C are: n=5, 10, 44, 2, 10, 7. Error bars depict the SEM of a sample. Levels of IL-8 in nasal fluid (n=32) were
plotted against the chemotactic index and a weak positive correlation was found (p=0.03, R
2=0.14) (D). HIES-patients 1 and 2 are marked ‘‘1’’ and
‘‘2’’. Statistical analyses in figure A, B and C were performed with Mann Whitney U-test and for figure D a correlation test was used.
doi:10.1371/journal.pone.0029316.g003
Table 2. Summary of results obtained in the study.
AMP induction
LL-37 HNP1–3 Chemotaxis PBMC (IL-17A)
Controls ++ + +
ND group ++ + +
IgA/IgG ++ 2 +
HIES 22 + 2
CVID 22 2 +/2
A summary of the responses for the different patient groups. A ‘‘+’’-sign
denotes a significant response with regards to AMP-induction, chemotaxis or
IL17-A release from PBMC-cultures, respectively. A ‘‘2’’-sign represent a non-
significant response. ‘‘+/2’’ means that CVID-patients respond with a significant
increase in IL17-A after stimulation with SEB, but not candida. Moreover, CVID-
patients responded significantly less than healthy controls (see also fig. 4A and
B).
doi:10.1371/journal.pone.0029316.t002
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antigen stimulation with release of IL-17A (n.s. for Candida antigen
and p=0.0009 for SEB) (Fig. 4A and B). Interestingly, this release
was significantly lower than the release observed for cells obtained
from healthy controls (p=0.0185 for Candida and p=0.0025 for
SEB, table 2). Thus, these results imply that CVID-patients –
similarly to HIES patients – have an impaired release of IL-17A
from SEB- and Candida stimulated PBMCs. If this problem stems
from aberrant recognition of antigen or intrinsic abnormalities in
IL-17A production, remains to be elucidated.
The major findings of this report are summarized in table 2. A
(+)-sign in columns ‘‘LL-37’’ and/or ‘‘HNP1–3’’ represent an
increased release of LL-37 and/or HNP1–3 in response to
pathogenic bacteria comparable to that of the control group,
whereas those denoted by a (2)-sign exhibit an impaired release.
Patient groups marked with (+) in the ‘‘Chemotaxis’’ column
showed a chemotactic activity against healthy PMNs comparable
to the control group and a (2)-sign denotes impaired or lack of
chemotactic activity. A (+)-sign in the ‘‘PBMC’’ column refers to a
capacity of the PBMCs to release IL-17A in response to Candida
or SEB antigens, a (2)-sign is indicative of an impaired IL-17A
release, whereas +/2 is indicative of statistically significant
response to SEB antigen, but not to Candida antigen (CVID-
patients).
Discussion
In this study we investigated if altered levels of AMPs in nasal
fluid may explain why PID patients frequently acquire RTIs. A
key finding was that most patients and healthy controls responded
to pathogenic bacteria with an increased AMP expression in nasal
fluid. However, this response was impaired in CVID and HIES
patients, which may be due to a low response from IL-17A
producing cells, including CD4+ Th17-cells, NK-cells or mono-
cytes [29]. However, IL-17A has been described as the ‘‘signature
cytokine’’ for Th17-cells and is – together with IL-22 – implicated
in mucosal immunity against bacterial and fungal infections [15].
The role of IL-17A and IL-22 producing immune cells in mucosal
Figure 4. Stimulation of PBMCs with Candida antigen and SEB. PBMCs isolated from healthy controls and patients were stimulated with
Candida antigen (A) and SEB (B), respectively. After 5 days, IL-17A levels were measured in the supernatants with ELISA. U; unstimulated, C; stimulated
with Candida antigen, and S; stimulated with SEB antigen. The number of samples are n=15, 15, 9, 9, 17, 17, 2, 2, 8, 8 (A), n=15, 9, 9, 6, 17, 16, 2, 1, 8,
8 (B). Bars represent the mean value. Mann Whitney U-test was used in A and B.
doi:10.1371/journal.pone.0029316.g004
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mucosa during infection where they orchestrate local immune
responses, such as neutrophil chemotaxis (via IL-8) or induction of
AMP synthesis (direct effects of IL-17A and IL-22 on epithelial
cells) [15]. Our data indicate that HIES and CVID patients
exhibit a similar impaired release of AMPs into nasal fluid, but
with separate immunological pathways involved (summarized in
table 2 and figure 5).
The two HIES patients with STAT3 gene mutations responded
with very low levels of IL-17A in antigen-stimulated PBMCs,
which is in line with a previous study [19]. Nasal fluid from these
two patients contained low levels of LL-37 and completely lacked
HNP1–3. LL-37 is expressed by both immune and epithelial cells,
whereas HNP1–3 is mainly present in neutrophils. Therefore, low
or absent HNP1–3 in nasal fluid indicate an impaired recruitment
of neutrophils to the nasal compartment. Indeed, HIES patients
often suffer from ‘‘cold abscesses’’; bacterial skin infection without
neutrophil infiltration and classical signs of inflammation [21]. In
chemotaxis experiments, nasal fluid from the two HIES patients
induced normal chemotaxis in neutrophils derived from healthy
individuals. Indeed, IL-8 levels in nasal fluid from these two HIES-
patients were similar to controls (Figure 3D, numbers ‘‘1’’ and
‘‘2’’), despite an almost complete lack of IL-17A production in
PBMCs. This was unexpected but suggests that the low AMP
levels in nasal fluid of HIES patients is not caused by a lack of
chemotactic signals, but rather that neutrophils derived from
HIES patients have impaired chemotaxis. In fact, it has been
known since 1983 that neutrophils from HIES patients (Job’s
syndrome) do not respond properly to chemotactic signals such as
complement (C5a) [30]. Moreover, deletion of the STAT3 gene in
mice resulted in impaired neutrophil chemotaxis [31] and
neutrophils from HIES patients display low levels of CXCR1, a
receptor for IL-8 [32]. Thus, it is possible that the frequent
mucosal infections among HIES patients is related to an impaired
STAT3 mediated neutrophil migration, rather than impaired
Th17 responses (Table 2 and Fig. 5).
In contrast, CVID patients were reported to have normally
migrating neutrophils [30]. Nevertheless, we detected aberrant
AMP responses to pathogenic bacteria in these patients. This
could be explained by the significantly decreased chemotactic
activity of nasal fluid from CVID patients (Fig. 3C). In addition,
PBMCs derived from CVID patients responded with a weaker IL-
17A response to SEB and Candida antigen, compared to control
PBMCs (Fig. 4A and B). Thus, these data are in line with the
current hypothesis that lack of IL-17A leads to a lower expression
of mucosal AMPs, possibly caused by an aberrant chemotactic
signal (Table 2 and Fig. 5). A recent paper from Barbosa et al,
describes in detail that both CVID-patients and agammaglobu-
linemic patients (XLA-patients) exhibit Th17-cell disturbances,
suggesting that B-cells are important for development of functional
Th17-cells [33]. These data are in line with our results on CVID-
patients but does not explain the mechanisms involved. Unfortu-
nately, the low number of XLA-patients in our study precludes
any conclusions regarding the role of Th17-cells in this disease.
One possible explanation to the low IL-17A release from CVID-
patients’ PBMCs is that it reflects a general T-cell defect among
CVID-patients, rather than a specific Th17-cell problem.
Previously, CVID patients were shown to have lower numbers
Figure 5. Impaired release of AMPs into nasal fluid of HIES- and CVID patients – A proposed model. HIES patients (blue lines) exhibit an
impaired production of IL-17A and their nasal fluid contain very low levels of LL-37 and HNP1–3 despite normal chemotactic activity and IL-8 levels.
This may be explained by defects in expression of the IL-8 receptor CXCR1, resulting in non-responding neutrophils. CVID patients (red lines) also
exhibited a dysregulated release of AMPs, which may be explained by the low chemotactic activity of nasal fluid as well as an impaired Th17
response. However, CVID patients have, in contrast to HIES patients, normally responding neutrophils, but this may not be sufficient, since the
chemotactic signal is too weak.
doi:10.1371/journal.pone.0029316.g005
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is in contrast to HIES-patients where a defined mutation in
STAT3 is the underlying cause of the lack of Th17-cells, without
general T-cell abnormalities [19]. SEB and candida induce Th17-
cell differentiation by distinct pathways; SEB is a general T-cell
activator by virtue of its superantigenic properties [36] whereas
candida activates antigen presenting cells (APCs) via dectin-1
ligation [37]. Notably, SEB stimulation – but not candida
stimulation – resulted in a small but statistically significant increase
in IL-17A release from PBMCs of CVID-patients (figure 4A and
B). In fact, it has been shown that CVID-patients have low
numbers of dendritic cell subsets in peripheral blood [38]. Thus, it
is possible that CVID-patients may have deficiencies both in the
T- and dendritic cell compartments, although this speculation
needs further work to become established. Interestingly, the CVID
group contained one outlier with high IL-17A production. This
patient was originally diagnosed with selective IgA-deficiency and
has gradually declined in IgG-levels and was given the CVID
diagnosis 2 years ago, which could explain the relatively high IL-
17A levels (Fig. 4A and B, arrows).
We believe that the results presented here give further insight
into the complex regulation of AMP production at mucosal
surfaces of the respiratory tract in general and among PID patients
in particular. The data presented here could also serve as a starting
point for future studies, since the detailed mechanism for impaired
IL-17A release among CVID patients merits further investigations.
Finally, our data show that certain primary immune disorders,
such as CVID and HIES are associated with mucosal dysregu-
lation of AMP release, which provide exciting new avenues for
clinical trials with AMP-inducing agents, such as vitamin D.
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